24/7 Customer Support
The global rapid microbiology testing market is expected to witness significant growth in the coming years, driven by increasing demand for faster and more accurate testing methods in various industries. The market is expected to be valued at USD 8.8 billion by 2031 from USD 4.3 billion in 2022, growing at a CAGR of 9.24% from 2023-2031.
The United States clinical laboratory services market is expected to reach a valuation of US$ 125.6 Bn by 2030 from 93.0 billion in 2022 at a CAGR of 4.2% over the forecast period 2023-2030.
The Global Soft tissue sarcoma (STS) Market has been estimated to grow with a CAGR of 7.4% during the forecast year and was holding a revenue of US$ 3,595.41 Mn in 2022 and is projected to reach US$ 6,465.70 Mn by 2030.
Global medical rehabilitation services market is estimated to grow at a CAGR of 7.4% during the forecast period of 2023–2031 and is expected to reach a valuation of US$ 558.7 Mn by 2031 from 297.60 Mn in 2022.
The Asia Pacific stem cell therapy market is poised for substantial growth in the coming years, with a projected compound annual growth rate (CAGR) of 10.29% between 2023 and 2031. This growth is expected to drive the market value up to US$ 3,420.05 Mn by 2031, following a successful revenue performance of US$ 1,453.61 Mn in 2022.
Global exosome research market was valued at US$ 174.94 million in 2022 and is anticipated to record a revenue of US$ 1,158.04 Million by 2031 at a CAGR of 24.4% over the forecast period of 2023 to 2031.
India specialty drug distribution market generated a revenue of US$ 2,045.35 million in 2022 and is estimated to reach a valuation of US$ 5,997.7 million by 2031 at a CAGR of 12.93% during the forecast period 2023–2031.
ASEAN nutritional supplements market generated revenue of US$ 7,366.8 million in 2022 and it is estimated to reach valuation of US$ 14,847.3 million by 2031 at a CAGR of 8.4% during the forecast period, 2023–2031.
ASEAN & US corporate wellness market is anticipated to reach valuation of US$ 30.82 Bn in 2030 from US$ 18.29 Bn in 2021. The market is expected to register healthy growth at a CAGR of 5.88 % during the forecast period 2022–2030.
Japan pet cancer therapeutics market was valued at US$ 14.0 Million in 2021 and is projected to reach a valuation of US$ 26.1 Million by 2031 at a CAGR of 7.3% during the forecast period 2023-2031.